ClinicalTrials.gg
RecruitingNCT06796309TRAK-RURALUpdated Apr 8, 2025

Assessment of Rural Health Care: Implementing TRAK Digital Tool for Quality and Accessible Services

An interventional study of Trak Telerehabilitation Platform and Conventional Rehabilitation Program in Shoulder Pain, sponsored by Trak Health Solutions S.L.. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-08.

Sponsored by Trak Health Solutions S.L. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2025, 1 year 6 months ago, but the record still lists the study as recruiting.
  • Registered 11 months after the study started (first participant enrolled Feb 2024, registered Jan 2025).
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Shoulder Pain with a site in Spain — 10 open to participants now, 10 under way, none of them phase 3. Shoulder Pain · Spain.

Planned enrollment
3rd of 49
95 · median 50
Started
2024
with 7 others
No phase
47 of 52
10 open now
Registered
42nd of 52
by date

Among the 52 studies in Shoulder Pain with a site in Spain, this one is the 3rd largest by planned enrollment of the 49 interventional ones that give a count, is one of 8 that started in 2024, is one of 47 with no phase, and was the 42nd registered.

Shoulder Pain

738 studies on the registry are indexed under Shoulder Pain; 168 are open to participants now.

Browse Shoulder Pain studies →

Open to participants now

10 of the 52 studies in Shoulder Pain with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 90 Shoulder Pain studies recruiting now, 25 (28%) set no upper age limit and 55 (61%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Shoulder Pain with a site in Spain, or all of them as a file.
02

Study summary

This clinical trial aims to analyze the usability and degree of satisfaction of two populations, healthcare personnel (Population 1) in rural areas and their patients (Population 2), with the TRAK tele-rehabilitation tool.

Participants will undergo telerehabilitation treatment through the TRAK platform for eight weeks (treatment group) or follow an at home exercise protocol (control group).

Read the detailed description

The recruitment process for this study is aimed at patients with shoulder pain (population 2) and healthcare personnel (population 1).

After the initial screening, individuals who meet the study's predefined inclusion criteria will be invited to participate. Before enrollment, written informed consent will be obtained from all participants, ensuring ethical compliance and respect for individual autonomy.

The healthcare personnel (population 1) will use Trak during the entire study period, from the time of entry into the study to the time of exit.

The study cohort will consist of patients randomly assigned to the experimental group (EG) and the control group (CG) on the first in person visit for the population 2 (patients). Regardless of group assignment, all patients will undergo baseline health assessments, ensuring that their individual needs are met. The satisfaction questionnaire will be deferred until post-intervention for both groups.

Participants in both groups will begin by filling out the Quality of Life Scale (EuroQol 5). and Shoulder Functional Assessment Scale (SPADI-Br) on the first visit.

In the case of the treatment group (EG), the participants will use the platform following the treatment prescribed by their health professionals for a period of 2 months. in the case of the control group (CG), the patients will follow the usual clinical practice treatment (they will receive the exercise protocol in paper format).

At the end of the treatment period, a final face-to-face visit will be made.

Patients (population 2) will undergo 8 weeks of treatment through the TRAK tool (https://www.trakphysio.com/es/) in the EG. Patients from the EG will carry out the treatment through the platform at home, and those from the CG will follow an on paper exercise protocol based on the usual (in-person) clinical practice methodology. Both groups will perform exercises in these rehabilitation sessions to improve shoulder mobility.

The results will be evaluated using different métrics, such as Telemedicine Usability Questionnaire (TUQ) and Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ), wich are the main ones, number of patients using the platform, the EuroQol-5D and the shoulder functional evaluation scale (SPADI-Br). These scales will be completed on paper at the beginning and end of the study for both groups.

03

Conditions studied

  • Shoulder Pain

Browse trials for

Keywords

  • shoulder pain
  • telerehabilitation
  • telemedicine
  • exercise program
  • physiotherapy
  • healthcare personnel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria population 1:

  • They carry out their activity in a rural environment.
  • That they know how to use the tool.
  • That they have a device with which to use the tool.
  • That they have an e-mail address.
  • That they have an Internet connection.
  • That they have signed the form.

Exclusion Criteria population 1:

  • N/A

Inclusion Criteria population 2:

  • Seniors.
  • Patients with omalgia of more than 6 months of evolution.
  • Who have a device with which to use the tool.
  • Who have a device with which to use the tool.
  • Who have an Internet connection.
  • Who have an e-mail address.
  • Who have signed the informed consent form.

Exclusion Criteria population 2:

  • Patients with cognitive impairment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
95 participants (estimated)

Study arms

  • Experimental
    TRAK treatment group (Population 2)

    Patients will use Trak platform for 8 weeks (2 months) for their exercise program. The use of the tool involves performing the corresponding therapeutic exercise program through it. The frequency of the exercises will be determined by the healthcare professional responsible for the patient, based on the needs identified during the assessment, ranging from 3 to 7 days per week.

    Other: Trak Telerehabilitation Platform

  • Active comparator
    Control Group (Population 2)

    Patients in the control group will undergo the same rehabilitation period (8 weeks) but following standard clinical practice.

    Other: Conventional Rehabilitation Program

  • Other
    Healthcare professional Group (Population 1)

    Healthcare professionals who will have access to the tool to prescribe exercise sessions for their patients, monitor their progress, adapt and modify the exercise program, communicate with patients to address their questions, and track their progress over time.

    Other: Trak Telerehabilitation Platform

Interventions

  • OtherTrak Telerehabilitation Platform

    The exercise protocol designed is carried out through TRAK, the digital rehabilitation tool.

  • OtherConventional Rehabilitation Program

    Exercise protocol with the methodology of conventional clinical practice.

06

What researchers measure

Primary outcomes

  1. Telemedicine Usability Questionnaire (TUQ).

    The TUQ is a questionnaire specifically designed to measure (from 17 to 109 points) the usability of telemedicine systems from the perspective of healthcare personnel.

    Time frame: Last visit, week 8

  2. Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ).

    Scale designed to evaluate the satisfaction and usefulness perceived by telemedicine users from 17 to 85 points.

    Time frame: Last visit, week 8

Secondary outcomes

  1. European quality of life 5 dimension questionnaire (EuroQol-5D)

    Generic and standardized questionnaire developed to describe and assess health-related quality of life. This questionnaire has an EVA scale from 0 to 100 and 5 questions that gives a 5 digit patient profile (From 11111 if the patients does not have problems on any item to 33333 if the patients have severe problems). The items valued are personal care, daily activities, mobility, pain and anxiety/depression.

    Time frame: week 1 and 8

  2. Focus on Shoulder Pain and Disability Index (SPADI-Br).

    The SPADI-Br was designed to evaluate the degree of shoulder pain and discomfort in performing activities of daily living from 0 to 130 points.

    Time frame: week 1 and 8

  3. Number of patients using the platform

    The total number of patients who are using the TRAK platform.

    Time frame: week 8

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for May 2025, 14 months after the start.

Of 356 interventional studies with no phase under Shoulder Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 27. This study's planned 14 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 28, 2025
StartActual
Feb 7, 2024
Primary completionEst.
May 1, 2025
CompletionEst.
May 1, 2025
Last update
Apr 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06796309
Lead sponsor
Trak Health Solutions S.L.
Collaborators
University Hospital Gregorio Marañón
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Feb 7, 2024
Primary completion
May 1, 2025 (estimated)
Completion
May 1, 2025 (estimated)
Last update
Apr 8, 2025

Study contacts

JUAN F DUARTE MENDOZA
Contact
juanfernando@trak.es
+34 677 33 4869
ANA VADILLO CORTÁZAR
principal investigator · Hospital Universitario del Sureste

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion